Regulatory and health technology assessment of cell and gene therapies in Europe: Convergence or divergence?

被引：0
|
作者：
Hoogendoorn, Mark [1 ]
Fabriek, Babs [2 ]
Bloem, Lourens T. [1 ]
机构：
[1] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Div Pharmacoepidemiol & Clin Pharmacol, Utrecht, Netherlands
[2] Dutch Med Evaluat Board, Utrecht, Netherlands
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2023年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
61
引用
收藏
页码：16 / 16
页数：1
相关论文
共 50 条
  • [41] ORPHAN DRUGS: HEALTH TECHNOLOGY ASSESSMENT AND PRICING IN EUROPE
    Jaroslawski, S.
    Toumi, M.
    Korchagina, D.
    Jadot, G.
    VALUE IN HEALTH, 2018, 21 : S24 - S24
  • [42] Development of health technology assessment in Europe -: A personal perspective
    Jonsson, E
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2002, 18 (02) : 171 - 183
  • [43] Health technology assessment of surgical therapies for benign gynaecological disease
    Owusu-Ansah, Richard
    Gatongi, David
    Chien, Patrick F. W.
    BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY, 2006, 20 (06) : 841 - 879
  • [44] How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy?
    Michael Drummond
    Oriana Ciani
    Giulia Fornaro
    Claudio Jommi
    Eva Susanne Dietrich
    Jaime Espin
    Jean Mossman
    Gerard de Pouvourville
    BMC Health Services Research, 23
  • [45] How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy?
    Drummond, Michael
    Ciani, Oriana
    Fornaro, Giulia
    Jommi, Claudio
    Dietrich, Eva Susanne
    Espin, Jaime
    Mossman, Jean
    de Pouvourville, Gerard
    BMC HEALTH SERVICES RESEARCH, 2023, 23 (01)
  • [46] Health technology in Europe - Regulatory framework and industry perspectives of the "new approach"
    Pallikarakis, Nicolas
    Moore, Richard
    IEEE ENGINEERING IN MEDICINE AND BIOLOGY MAGAZINE, 2007, 26 (03): : 14 - 17
  • [47] Gene profiling for assessment of cell-based therapies
    Engman, David M.
    CELL CYCLE, 2011, 10 (13) : 2054 - 2054
  • [48] Biosafety testing of cell and gene therapies; rapid methods and regulatory expectations
    Sheridan, S.
    Spreng, K.
    McKee, M.
    Goodier, R.
    HUMAN GENE THERAPY, 2019, 30 (08) : A29 - A29
  • [49] HEALTH ECONOMIC MODELLING APPROACHES IN CELL AND GENE THERAPIES
    Mumford, A.
    Ringger, D.
    Lewis, H.
    VALUE IN HEALTH, 2022, 25 (07) : S509 - S509
  • [50] The impact of parallel regulatory-health technology assessment scientific advice on clinical development. Assessing the uptake of regulatory and health technology assessment recommendations
    Tafuri, Giovanni
    Lucas, Ines
    Estevao, Steve
    Moseley, Jane
    d'Andon, Anne
    Bruehl, Hannah
    Gajraj, Elangovan
    Garcia, Sonia
    Hedberg, Niklas
    Massari, Marco
    Molina, Andrea
    Obach, Merce
    Osipenko, Leeza
    Petavy, Frank
    Petschulies, Marco
    Pontes, Caridad
    Russo, Pierluigi
    Schiel, Anja
    Van de Casteele, Marc
    Zebedin-Brandl, Eva-Maria
    Rasi, Guido
    Vamvakas, Spiros
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (05) : 1013 - 1019
12345